Unlocking Breakthrough Cancer Treatments: A Game-Changer for Patients
This study evaluates the clinical actionability and benefit of genome-targeted cancer therapies recommended by the NCCN. Utilizing frameworks like ESCAT and ESMO-MCBS, the study found that only one-eighth of the treatments were rated as having high clinical benefits, highlighting a crucial need to align cancer treatment recommendations with expected outcomes.